

Geoffrey Barnes

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5522018/publications.pdf>

Version: 2024-02-01

166
papers

5,763
citations

257450

24
h-index

82547

72
g-index

177
all docs

177
docs citations

177
times ranked

9766
citing authors

#	ARTICLE	IF	CITATIONS
1	Anticoagulation Changes Following Major and Clinically Relevant Nonmajor Bleeding Events in Non-valvular Atrial Fibrillation Patients. <i>Journal of Pharmacy Practice</i> , 2023, 36, 542-547.	1.0	2
2	SARS-CoV-2 Vaccination-Induced Thrombotic Thrombocytopenia: A Rare but Serious Immunologic Complication. <i>Annual Review of Medicine</i> , 2023, 74, 65-74.	12.2	8
3	The burden of undertreatment and non-treatment among patients with non-valvular atrial fibrillation and elevated stroke risk: a systematic review. <i>Current Medical Research and Opinion</i> , 2022, 38, 7-18.	1.9	13
4	Factors Associated With Inferior Vena Cava Filter Placement and Retrieval for Patients With Cancer-Associated Thrombosis. <i>American Journal of Medicine</i> , 2022, 135, 478-487.e5.	1.5	2
5	Management Strategies Following Slightly Out of Range INRs: Watchful Waiting vs. Dose Changes. <i>Blood Advances</i> , 2022, , .	5.2	0
6	Development of a multicomponent implementation strategy to reduce upper gastrointestinal bleeding risk in patients using warfarin and antiplatelet therapy, and protocol for a pragmatic multilevel randomized factorial pilot implementation trial. <i>Implementation Science Communications</i> , 2022, 3, 8.	2.2	2
7	Implementing an electronic health record dashboard for safe anticoagulant management: learning from qualitative interviews with existing and potential users to develop an implementation process. <i>Implementation Science Communications</i> , 2022, 3, 10.	2.2	10
8	Anticoagulant drug-drug interactions: Highlighting the need for antithrombotic stewardship and shared decision making. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, e12662.	2.3	6
9	Apixaban has superior effectiveness and safety compared to rivaroxaban in patients with commercial healthcare coverage: A population-based analysis in response to <sc>CVS</sc> 2022 formulary changes. <i>American Journal of Hematology</i> , 2022, 97, .	4.1	3
10	Call to Action: Translating Scientific Research Into Real-World Change Through Implementation Science and Community-Engaged Research. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2022, 15, CIRCOUTCOMES122009031.	2.2	1
11	Predictors of Early (0-7 Days) and Late (8-30 Days) Readmission in a Cohort of Acute Coronary Syndrome Patients. <i>International Journal of Medical Students</i> , 2022, 10, 38-48.	0.5	2
12	Randomized evaluation of decision support interventions for atrial fibrillation: Rationale and design of the RED-AF study. <i>American Heart Journal</i> , 2022, 248, 42-52.	2.7	6
13	Association of adding antiplatelet therapy to warfarin for management of venous thromboembolism with bleeding and other adverse events. <i>Vascular Medicine</i> , 2022, 27, 382-384.	1.5	2
14	Outcomes of Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Valvular Heart Disease. <i>Current Cardiology Reports</i> , 2022, 24, 731-738.	2.9	1
15	Thrombotic and bleeding events, mortality, and anticoagulant use among 546,656 hospitalized patients with COVID-19 in the United States: a retrospective cohort study. <i>Journal of Thrombosis and Thrombolysis</i> , 2022, 53, 766-776.	2.1	9
16	Maintaining Implementation through Dynamic Adaptations (MIDAS): protocol for a cluster-randomized trial of implementation strategies to optimize and sustain use of evidence-based practices in Veteran Health Administration (VHA) patients. <i>Implementation Science Communications</i> , 2022, 3, 53.	2.2	0
17	Thromboembolic prevention and anticoagulant therapy during the COVID-19 pandemic: updated clinical guidance from the anticoagulation forum. <i>Journal of Thrombosis and Thrombolysis</i> , 2022, 54, 197-210.	2.1	29
18	Efficacy and Safety Considerations With Dose-Reduced Direct Oral Anticoagulants. <i>JAMA Cardiology</i> , 2022, 7, 747.	6.1	15

#	ARTICLE	IF	CITATIONS
19	A call to action: MTHFR polymorphisms should not be a part of inherited thrombophilia testing. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, e12739.	2.3	11
20	Annals for Hospitalists Inpatient Notes - Venous Thromboembolism Prophylaxis in COVID-19: Making Sense of the Evidence. <i>Annals of Internal Medicine</i> , 2022, 175, HO2-HO3.	3.9	1
21	Association of Antisecretory Drugs with Upper Gastrointestinal Bleeding in Patients Using Oral Anticoagulants: A Systematic Review and Meta-Analysis. <i>American Journal of Medicine</i> , 2022, 135, 1231-1243.e8.	1.5	4
22	Comparison of Patient Outcomes Before and After Switching From Warfarin to a Direct Oral Anticoagulant Based on Time in Therapeutic Range Guideline Recommendations. <i>JAMA Network Open</i> , 2022, 5, e2222089.	5.9	3
23	A call to action for anticoagulation stewardship. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, e12757.	2.3	15
24	Editorial commentary: Preventing venous thromboembolism in non-major orthopedic surgery: Generalizing recommendations for heterogenous patient populations. <i>Trends in Cardiovascular Medicine</i> , 2021, 31, 512-514.	4.9	0
25	Venous thrombosis epidemiology, pathophysiology, and anticoagulant therapies and trials in severe acute respiratory syndrome coronavirus 2 infection. <i>Journal of Vascular Surgery: Venous and Lymphatic Disorders</i> , 2021, 9, 23-35.	1.6	35
26	Inappropriate Prescription of Direct Oral Anticoagulant Starter Packs. <i>American Journal of Medicine</i> , 2021, 134, 370-373.e1.	1.5	1
27	Response: Patient and caregiver engagement in venous thromboembolism research. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, 247-247.	2.3	0
28	Anticoagulant medication adherence for cancer-associated thrombosis: A comparison of LMWH to DOACs. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 212-220.	3.8	27
29	Using Health Systems Engineering Approaches to Prepare for Tailoring of Implementation Interventions. <i>Journal of General Internal Medicine</i> , 2021, 36, 178-185.	2.6	4
30	Adverse outcomes associated with inappropriate direct oral anticoagulant starter pack prescription among patients with atrial fibrillation: a retrospective claims-based study. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 51, 1144-1149.	2.1	1
31	The IMPact of untreated non-Valvular atrial fibrillation on short-term clinical and economic outcomes in the US Medicare population: the IMPROVE-AF model. <i>Journal of Medical Economics</i> , 2021, 24, 1070-1082.	2.1	2
32	Clinical and sociodemographic factors associated with anticoagulant use for cancer associated venous thromboembolism. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 52, 214-223.	2.1	3
33	Harnessing Twitter to empower scientific engagement and communication: The ISTH 2020 virtual congress experience. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, 253-260.	2.3	8
34	Reduction in epistaxis and emergency department visits in patients taking warfarin after implementation of an education program. <i>Thrombosis Research</i> , 2021, 199, 119-122.	1.7	4
35	PERTinent new insights into venous thromboembolism risk and management in hospitalized patients with COVID-19. <i>Vascular Medicine</i> , 2021, 26, 434-436.	1.5	0
36	Continuing to Advance the Venous Agenda: Long-Term Insights From the CAVA Trial. <i>Journal of the American Heart Association</i> , 2021, 10, e021659.	3.7	2

#	ARTICLE	IF	CITATIONS
37	Trends in Venous Thromboembolism Anticoagulation in Patients Hospitalized With COVID-19. JAMA Network Open, 2021, 4, e2111788.	5.9	43
38	Adverse Events Associated With the Addition of Aspirin to Direct Oral Anticoagulant Therapy Without a Clear Indication. JAMA Internal Medicine, 2021, 181, 817.	5.1	33
39	Trends in Calcium Channel Blocker Use in Patients with Heart Failure with Reduced Ejection Fraction and Comorbid Atrial Fibrillation. American Journal of Medicine, 2021, 134, 1413-1418.e1.	1.5	5
40	Comparison of temporary interruption with continuation of direct oral anticoagulants for low bleeding risk procedures. Thrombosis Research, 2021, 203, 27-32.	1.7	5
41	Implementation Science Opportunities in Cardiovascular Medicine. Circulation: Cardiovascular Quality and Outcomes, 2021, 14, e008109.	2.2	2
42	Effectiveness and Safety of Direct Oral Anticoagulants Versus Warfarin in Patients With Valvular Atrial Fibrillation. Annals of Internal Medicine, 2021, 174, 910-919.	3.9	25
43	Improving preprocedure antithrombotic management: Implementation and sustainment of a best practice alert and pharmacist referral process. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12558.	2.3	1
44	To Deprescribe or Not to Deprescribe Aspirin—A Clear Indication Is the Challenge—Reply. JAMA Internal Medicine, 2021, 181, 1541.	5.1	1
45	Adverse events in patients taking apixaban or rivaroxaban who have undergone bariatric surgery: a retrospective case series. Journal of Thrombosis and Thrombolysis, 2021, , 1.	2.1	3
46	Early (0-7 day) and late (8-30 day) readmission predictors in acute coronary syndrome, atrial fibrillation, and congestive heart failure patients. Hospital Practice (1995), 2021, 49, 364-370.	1.0	1
47	Use of Social Media in the Practice of Medicine. American Journal of Medicine, 2021, , .	1.5	2
48	Cardiovascular and major bleeding outcomes with antiplatelet and direct oral anticoagulants in patients with acute coronary syndrome and atrial fibrillation: A population-based analysis. American Heart Journal, 2021, 242, 71-81.	2.7	0
49	Effectiveness and Safety of Direct Oral Anticoagulants Versus Warfarin in Patients With Valvular Atrial Fibrillation. Annals of Internal Medicine, 2021, 174, 1490.	3.9	3
50	Standard Versus Higher Intensity Anticoagulation for Patients With Mechanical Aortic Valve Replacement and Additional Risk Factors for Thromboembolism. American Journal of Cardiology, 2021, 159, 100-106.	1.6	1
51	DOAC drug levels: Does “knowing” lead to safer care?. Thrombosis Research, 2021, 208, 127-128.	1.7	0
52	Outcomes of Direct Oral Anticoagulants with Aspirin Versus Warfarin with Aspirin for Atrial Fibrillation and/or Venous Thromboembolic Disease. Blood, 2021, 138, 179-179.	1.4	0
53	Integrating Lean Thinking and Implementation Science Determinants Checklists for Quality Improvement: A Scoping Review. American Journal of Medical Quality, 2020, 35, 330-340.	0.5	9
54	Pulmonary embolism response team implementation improves awareness and education among the house staff and faculty. Journal of Thrombosis and Thrombolysis, 2020, 49, 54-58.	2.1	10

#	ARTICLE	IF	CITATIONS
55	Stroke and thromboembolism prevention in atrial fibrillation. <i>Heart</i> , 2020, 106, 10-17.	2.9	74
56	Applying population health approaches to improve safe anticoagulant use in the outpatient setting: the DOAC Dashboard multi-cohort implementation evaluation study protocol. <i>Implementation Science</i> , 2020, 15, 83.	6.9	14
57	Venous thromboembolism research priorities: A scientific statement from the American Heart Association and the International Society on Thrombosis and Haemostasis. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020, 4, 714-721.	2.3	6
58	Combining antiplatelet and anticoagulant therapy in cardiovascular disease. <i>Hematology American Society of Hematology Education Program</i> , 2020, 2020, 642-648.	2.5	21
59	Management of Anticoagulant Treatment and Anticoagulation-Related Complications in Nonagenarians. <i>Hamostaseologie</i> , 2020, 40, 292-300.	1.9	4
60	Emergency Department Clinician Perceptions of Implementing High-Sensitivity Troponin T Assay in an Academic Hospital Emergency Department. <i>American Journal of Medicine</i> , 2020, 133, e483-e494.	1.5	2
61	Antithrombotic Management of Venous Thromboembolism. <i>Journal of the American College of Cardiology</i> , 2020, 76, 2142-2154.	2.8	20
62	Comparison of 4 Acute Pulmonary Embolism Mortality Risk Scores in Patients Evaluated by Pulmonary Embolism Response Teams. <i>JAMA Network Open</i> , 2020, 3, e2010779.	5.9	26
63	Society of Interventional Radiology Clinical Practice Guideline for Inferior Vena Cava Filters in the Treatment of Patients with Venous Thromboembolic Disease. <i>Journal of Vascular and Interventional Radiology</i> , 2020, 31, 1529-1544.	0.5	104
64	Managing suspected venous thromboembolism when a pandemic limits diagnostic testing. <i>Thrombosis Research</i> , 2020, 196, 213-214.	1.7	1
65	Correcting Inappropriate Prescribing of Direct Oral Anticoagulants: A Population Health Approach. <i>Journal of the American Heart Association</i> , 2020, 9, e016949.	3.7	10
66	Extended Venous Thromboembolism Prophylaxis in Medically Ill Patients: An NATF Anticoagulation Action Initiative. <i>American Journal of Medicine</i> , 2020, 133, 1-27.	1.5	18
67	Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research. <i>Thrombosis and Haemostasis</i> , 2020, 120, 1004-1024.	3.4	206
68	Periprocedural bridging anticoagulation in patients with venous thromboembolism: A registry-based cohort study. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2025-2030.	3.8	6
69	Venous Thromboembolism Research Priorities: A Scientific Statement From the American Heart Association and the International Society on Thrombosis and Haemostasis. <i>Circulation</i> , 2020, 142, e85-e94.	1.6	24
70	“Reduce the Likelihood of Patient Harm Associated with the Use of Anticoagulant Therapy” Commentary from the Anticoagulation Forum on the Updated Joint Commission NPSG.03.05.01 Elements of Performance. <i>Joint Commission Journal on Quality and Patient Safety</i> , 2020, 46, 173-180.	0.7	7
71	The real world use of combined P-glycoprotein and moderate CYP3A4 inhibitors with rivaroxaban or apixaban increases bleeding. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 49, 636-643.	2.1	62
72	Assessment of a Best Practice Alert and Referral Process for Preprocedure Antithrombotic Medication Management for Patients Undergoing Gastrointestinal Endoscopic Procedures. <i>JAMA Network Open</i> , 2020, 3, e1920548.	5.9	10

#	ARTICLE	IF	CITATIONS
73	Use of apixaban and rivaroxaban in young adults with acute venous thromboembolism: a multi-center retrospective case series. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 50, 844-848.	2.1	7
74	COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2950-2973.	2.8	2,392
75	Thromboembolism and anticoagulant therapy during the COVID-19 pandemic: interim clinical guidance from the anticoagulation forum. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 50, 72-81.	2.1	362
76	A toolkit for the collection of thrombosis-related data elements in COVID-19 clinical studies. <i>Blood Advances</i> , 2020, 4, 6259-6273.	5.2	7
77	Periprocedural Bridging Anticoagulation: Measuring the Impact of a Clinical Trial on Care Delivery. <i>American Journal of Medicine</i> , 2019, 132, 109.e1-109.e7.	1.5	7
78	Clinical Safety Outcomes in Patients With Nonvalvular Atrial Fibrillation on Rivaroxaban and Diltiazem. <i>Annals of Pharmacotherapy</i> , 2019, 53, 21-27.	1.9	20
79	Assessment of Patient Nondisclosures to Clinicians of Experiencing Imminent Threats. <i>JAMA Network Open</i> , 2019, 2, e199277.	5.9	14
80	Cardiac Rehabilitation Use After Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2019, 73, 3148-3152.	2.8	19
81	Nation-Wide Use of Periprocedural Bridging Anticoagulation in Patients With Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2019, 124, 1549-1553.	1.6	3
82	Interventional Therapies for Acute Pulmonary Embolism: Current Status and Principles for the Development of Novel Evidence: A Scientific Statement From the American Heart Association. <i>Circulation</i> , 2019, 140, e774-e801.	1.6	241
83	Barriers to integrating direct oral anticoagulants into anticoagulation clinic care: A mixed-methods study. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2019, 3, 79-84.	2.3	6
84	Cost-Effectiveness of Bridging Anticoagulation Among Patients with Nonvalvular Atrial Fibrillation. <i>Journal of General Internal Medicine</i> , 2019, 34, 583-590.	2.6	4
85	Role of diabetes and insulin use in the risk of stroke and acute myocardial infarction in patients with atrial fibrillation: A Medicare analysis. <i>American Heart Journal</i> , 2019, 214, 158-166.	2.7	14
86	Anticoagulation and antiplatelet therapy in stable coronary artery disease: A multicenter survey. <i>Thrombosis Research</i> , 2019, 180, 25-27.	1.7	2
87	Creatinine monitoring patterns in the setting of direct oral anticoagulant therapy for non-valvular atrial fibrillation. <i>Journal of Thrombosis and Thrombolysis</i> , 2019, 48, 500-505.	2.1	5
88	Missed opportunities to prevent upper GI hemorrhage: The experience of the Michigan Anticoagulation Quality Improvement Initiative. <i>Vascular Medicine</i> , 2019, 24, 153-155.	1.5	9
89	Association of Adding Aspirin to Warfarin Therapy Without an Apparent Indication With Bleeding and Other Adverse Events. <i>JAMA Internal Medicine</i> , 2019, 179, 533.	5.1	37
90	Identifying Clinical Predictors of Switching From Direct Oral Anticoagulants to Warfarin. <i>Clinical Medicine Insights Therapeutics</i> , 2019, 11, 1179559X1983128.	0.4	0

#	ARTICLE	IF	CITATIONS
91	Venous thromboembolism: A clinician update. <i>Vascular Medicine</i> , 2019, 24, 122-131.	1.5	25
92	Predicting the Quality of Warfarin Therapy: Reframing the Question. <i>Thrombosis and Haemostasis</i> , 2019, 119, 509-511.	3.4	5
93	How the Results of a Randomized Trial of Catheter-Directed Thrombolysis Versus Anticoagulation alone for Submassive Pulmonary Embolism Would Affect Patient and Physician Decision Making: Report of an Online Survey. <i>Journal of Clinical Medicine</i> , 2019, 8, 215.	2.4	2
94	Annals for Hospitalists Inpatient Notes - Reaching for Higher Value in Health Care by Bringing Together Clinicians and Researchersâ€™ The Michigan Program on Value Enhancement. <i>Annals of Internal Medicine</i> , 2019, 171, HO2.	3.9	1
95	A multidisciplinary pulmonary embolism response team (PERT)â€™ experience from a national multicenter consortium. <i>Pulmonary Circulation</i> , 2019, 9, 1-10.	1.7	45
96	Periprocedural Antithrombotic Management from a Patient Perspective: A Qualitative Analysis. <i>American Journal of Medicine</i> , 2019, 132, 525-529.	1.5	3
97	Impact of Adding Aspirin to Direct Oral Anticoagulant Therapy without an Apparent Indication. <i>Blood</i> , 2019, 134, 787-787.	1.4	3
98	A Multi-Center Quality Improvement Intervention to Reduce the Inappropriate Use of Aspirin Among Patients Anticoagulated with Warfarin for Atrial Fibrillation or Venous Thromboembolism. <i>Blood</i> , 2019, 134, 788-788.	1.4	0
99	Endovascular ilio caval reconstruction for the treatment of ilio caval thrombosis: From imaging to intervention. <i>Vascular Medicine</i> , 2018, 23, 267-275.	1.5	17
100	What you don't know can kill you. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2018, 2, 8-10.	2.3	2
101	Treatment of submassive and massive pulmonary embolism: a clinical practice survey from the second annual meeting of the Pulmonary Embolism Response Team Consortium. <i>Journal of Thrombosis and Thrombolysis</i> , 2018, 46, 39-49.	2.1	19
102	Structure and function of anticoagulation clinics in the United States: an AC forum membership survey. <i>Journal of Thrombosis and Thrombolysis</i> , 2018, 46, 7-11.	2.1	21
103	Mind the gap: results of a multispecialty survey on coordination of care for peri-procedural anticoagulation. <i>Journal of Thrombosis and Thrombolysis</i> , 2018, 45, 403-409.	2.1	4
104	Evaluating the role of clinical pharmacists in pre-procedural anticoagulation management. <i>Hospital Practice (1995)</i> , 2018, 46, 16-21.	1.0	7
105	Peri-Procedural Management of Oral Anticoagulants in the DOAC Era. <i>Progress in Cardiovascular Diseases</i> , 2018, 60, 600-606.	3.1	25
106	Current Trends in Anticoagulation Bridging for Patients With Chronic Atrial Fibrillation on Warfarin Undergoing Endoscopy. <i>American Journal of Cardiology</i> , 2018, 121, 1548-1551.	1.6	4
107	Prevalence of and Factors Associated With Patient Nondisclosure of Medically Relevant Information to Clinicians. <i>JAMA Network Open</i> , 2018, 1, e185293.	5.9	108
108	377 A Multidisciplinary Pulmonary Embolism Response Team: Experience From the National Pulmonary Embolism Response Team Consortium Multicenter Registry. <i>Annals of Emergency Medicine</i> , 2018, 72, S148.	0.6	0

#	ARTICLE	IF	CITATIONS
109	Extended International Normalized Ratio testing intervals for warfarin-treated patients. <i>Journal of Thrombosis and Haemostasis</i> , 2018, 16, 1307-1312.	3.8	10
110	The impact of a multi-specialty team for high risk pulmonary embolism on resident and fellow education. <i>Vascular Medicine</i> , 2018, 23, 372-376.	1.5	24
111	Out-of-range INR results lead to increased health-care utilization in four large anticoagulation clinics. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2018, 2, 490-496.	2.3	1
112	Warfarin for prevention of thromboembolism in atrial fibrillation: comparison of patient characteristics and outcomes of the "Real-World" Michigan Anticoagulation Quality Improvement Initiative (MAQI2) registry to the RE-LY, ROCKET-AF, and ARISTOTLE trials. <i>Journal of Thrombosis and Thrombolysis</i> , 2018, 46, 316-324.	2.1	11
113	Learning to De-Adopt Ineffective Healthcare Practices. <i>American Journal of Medicine</i> , 2018, 131, 721-722.	1.5	5
114	Predicting the Post-Thrombotic Syndrome: Not Quite Ready for Prime Time. <i>Thrombosis and Haemostasis</i> , 2018, 118, 1345-1346.	3.4	2
115	Personalizing Bridging Anticoagulation in Patients with Nonvalvular Atrial Fibrillation—a Microsimulation Analysis. <i>Journal of General Internal Medicine</i> , 2017, 32, 464-470.	2.6	7
116	SAME-TT ₂ R ₂ predicts quality of anticoagulation in patients with acute venous thromboembolism: The MAQI ² experience. <i>Vascular Medicine</i> , 2017, 22, 197-203.	1.5	13
117	Root Cause Analysis of Adverse Events in an Outpatient Anticoagulation Management Consortium. <i>Joint Commission Journal on Quality and Patient Safety</i> , 2017, 43, 299-307.	0.7	6
118	EVALUATING THE ROLE OF ANTICOAGULATION CLINICAL PHARMACISTS FOR COORDINATING PERIPROCEDURAL ANTICOAGULATION. <i>Journal of the American College of Cardiology</i> , 2017, 69, 2488.	2.8	32
119	Evaluation of a pharmacist-led outpatient direct oral anticoagulant service. <i>American Journal of Health-System Pharmacy</i> , 2017, 74, 483-489.	1.0	34
120	Nuts and bolts of running a pulmonary embolism response team: results from an organizational survey of the National PERT ₂ Consortium members. <i>Hospital Practice (1995)</i> , 2017, 45, 76-80.	1.0	31
121	Discontinuation of Warfarin Therapy for Patients With Atrial Fibrillation. <i>JAMA Cardiology</i> , 2017, 2, 341.	6.1	1
122	A 37-Year-Old Man With Primary Antiphospholipid Syndrome Presenting With Respiratory Distress and Worsening Toe Ischemia. <i>Arthritis Care and Research</i> , 2017, 69, 1253-1259.	3.4	5
123	Prescribing trends of atrial fibrillation patients who switched from warfarin to a direct oral anticoagulant. <i>Journal of Thrombosis and Thrombolysis</i> , 2017, 43, 283-288.	2.1	22
124	Preventing recurrence from distal deep vein thrombosis: Still searching for answers. <i>Vascular Medicine</i> , 2017, 22, 525-526.	1.5	0
125	Risk factors for intracranial haemorrhage in patients with pulmonary embolism treated with thrombolytic therapy Development of the PE-CH Score. <i>Thrombosis and Haemostasis</i> , 2017, 117, 246-251.	3.4	51
126	Sociodemographic factors in patients continuing warfarin vs those transitioning to direct oral anticoagulants. <i>Blood Advances</i> , 2017, 1, 2536-2540.	5.2	7

#	ARTICLE	IF	CITATIONS
127	Barriers and facilitators to reducing frequent laboratory testing for patients who are stable on warfarin: a mixed methods study of de-implementation in five anticoagulation clinics. <i>Implementation Science</i> , 2017, 12, 87.	6.9	18
128	Inpatient Thrombophilia Testing: At What Expense?. <i>Journal of Hospital Medicine</i> , 2017, 12, 777-778.	1.4	1
129	Restarting antithrombotics after GI bleeding was linked to better outcomes in patients with AF. <i>Annals of Internal Medicine</i> , 2016, 164, JC33.	3.9	1
130	Diversity in the Pulmonary Embolism Response Team Model. <i>Chest</i> , 2016, 150, 1414-1417.	0.8	72
131	<i>Annals</i> for Hospitalists Inpatient Notes - Oral Anticoagulation for the Hospitalistâ€”Expanded Choices Improve Patient-Centered Care. <i>Annals of Internal Medicine</i> , 2016, 165, HO2.	3.9	0
132	Triple Oral Antithrombotic Therapy in Atrial Fibrillation and Coronary Artery Stenting: Searching for the Best Combination. <i>Seminars in Thrombosis and Hemostasis</i> , 2016, 42, 662-670.	2.7	12
133	Renal function in atrial fibrillation patients switched from warfarin to a direct oral anticoagulant. <i>Journal of Thrombosis and Thrombolysis</i> , 2016, 42, 566-572.	2.1	6
134	Cancer-Associated Venous Thromboembolism. Current Treatment Options in Cardiovascular Medicine, 2016, 18, 23.	0.9	9
135	Direct oral anticoagulants: unique properties and practical approaches to management. <i>Heart</i> , 2016, 102, 1620-1626.	2.9	16
136	Early career professionals: the mission of a task force. <i>Journal of Thrombosis and Haemostasis</i> , 2016, 14, 1328-1329.	3.8	3
137	Sleep apnea and peripheral artery disease: Bringing each other out of the shadows. <i>Atherosclerosis</i> , 2016, 251, 540-541.	0.8	2
138	Bridging Anticoagulation Before Colonoscopy. <i>JAMA Cardiology</i> , 2016, 1, 1076.	6.1	9
139	Use of Contraindicated Antiplatelet Medications in the Setting of Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2016, 9, 406-413.	2.2	4
140	Cost-Effectiveness of Percutaneous Closure of the Left Atrial Appendage in Atrial Fibrillation Based on Results From PROTECT AF Versus PREVAIL. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2016, 9, .	4.8	17
141	Use of decision aids for shared decision making in venous thromboembolism: A systematic review. <i>Thrombosis Research</i> , 2016, 143, 71-75.	1.7	6
142	Cost-Effectiveness of Dabigatran (150Âmg Twice Daily) and Warfarin in Patients â‰¥65ÂYears With Nonvalvular Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2016, 117, 54-60.	1.6	15
143	Reimagining Anticoagulation Clinics in the Era of Direct Oral Anticoagulants. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2016, 9, 182-185.	2.2	66
144	A Comparison of Socioeconomic Factors in Patients Continuing Warfarin Versus Those Transitioning to Direct Oral Anticoagulants (DOACs) for Venous Thromboembolic Disease or Atrial Fibrillation. <i>Blood</i> , 2016, 128, 1179-1179.	1.4	1

#	ARTICLE	IF	CITATIONS
145	Tobacco Use in Peripheral Artery Disease. <i>Journal of the American College of Cardiology</i> , 2015, 66, 1575-1576.	2.8	1
146	Recommendation on the nomenclature for oral anticoagulants: communication from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2015, 13, 1154-1156.	3.8	115
147	Recommendation on the nomenclature for oral anticoagulants: communication from the SSC of the ISTH: reply. <i>Journal of Thrombosis and Haemostasis</i> , 2015, 13, 2132-2133.	3.8	10
148	The changing characteristics of atrial fibrillation patients treated with warfarin. <i>Journal of Thrombosis and Thrombolysis</i> , 2015, 40, 488-493.	2.1	4
149	Engaging with quality improvement in anticoagulation management. <i>Journal of Thrombosis and Thrombolysis</i> , 2015, 39, 403-409.	2.1	16
150	Venous thromboembolism: Predicting recurrence and the need for extended anticoagulation. <i>Vascular Medicine</i> , 2015, 20, 143-152.	1.5	25
151	National Trends in Ambulatory Oral Anticoagulant Use. <i>American Journal of Medicine</i> , 2015, 128, 1300-1305.e2.	1.5	513
152	AREDS Formula, Warfarin, and Bleeding: A Case Report from the Michigan Anticoagulation Quality Improvement Initiative. <i>Case Reports in Medicine</i> , 2014, 2014, 1-4.	0.7	3
153	Perioperative Management of Oral Anticoagulants: A Focus on Target-Specific Oral Anticoagulants. <i>Hospital Practice (1995)</i> , 2014, 42, 62-67.	1.0	2
154	Warfarin use in atrial fibrillation patients at low risk for stroke: analysis of the Michigan Anticoagulation Quality Improvement Initiative (MAQI2). <i>Journal of Thrombosis and Thrombolysis</i> , 2014, 37, 171-176.	2.1	12
155	Venous thromboembolism: Diagnosis, treatment and the prevention of long-term complications. <i>Reviews in Vascular Medicine</i> , 2014, 2, 136-142.	0.4	0
156	The Predictive Ability of the CHADS2 and CHA2DS2-VASc Scores for Bleeding Risk in Atrial Fibrillation: The MAQI2 Experience. <i>Thrombosis Research</i> , 2014, 134, 294-299.	1.7	35
157	Abstract 17410: A Multiperspective Analysis of the Influence of Medicare Part D on the Cost-effectiveness of Dabigatran versus Warfarin. <i>Circulation</i> , 2014, 130, .	1.6	0
158	Effect of Dabigatran on Referrals to and Switching From Warfarin in Two Academic Anticoagulation Management Services. <i>American Journal of Cardiology</i> , 2013, 112, 387-389.	1.6	4
159	Use of warfarin for venous thromboembolism prophylaxis following knee and hip arthroplasty: results of the Michigan Anticoagulation Quality Improvement Initiative (MAQI2). <i>Journal of Thrombosis and Thrombolysis</i> , 2013, 35, 10-14.	2.1	13
160	Venous thromboembolism: a collaborative quality improvement model for practitioners, hospitals, and insurers. <i>Journal of Thrombosis and Thrombolysis</i> , 2012, 33, 274-279.	2.1	6
161	National trends in venous disease. <i>Journal of Vascular Surgery</i> , 2010, 51, 1467-1473.	1.1	21
162	Anticoagulation: where we are and where we need to go. <i>Journal of Thrombosis and Thrombolysis</i> , 2009, 28, 220-223.	2.1	8

#	ARTICLE	IF	CITATIONS
163	Anticoagulation: A Pathway to Clinical Effectiveness. American Journal of Medicine, 2009, 122, 126-128.	1.5	3
164	Dual antiplatelet agent failure: A new syndrome or clinical nonentity?. American Heart Journal, 2007, 154, 732-735.	2.7	12
165	Urinary Cyclic AMP in the Switch Process from Depression to Mania. British Journal of Psychiatry, 1974, 125, 457-458.	2.8	8
166	A Deadly Override. Circulation: Cardiovascular Quality and Outcomes, 0, , .	2.2	0